• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lucira and Loch Lomond Villa Announce Clinical Study to Tackle Tripledemic With First and Only Combination COVID-19 and Flu OTC Molecular Self-Test

    12/6/22 7:03:00 AM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $LHDX alert in real time by email
    • Lucira COVID-19 & Flu Test is the first and only combination over-the-counter (OTC) self-test with fast, molecular lab-quality results enabling mass testing of symptomatic residents, staff and visitors amid the aggressive COVID-19 and flu season in Canada.
    • Lucira's 99% accurate, differential molecular test can detect Influenza A/B and all strains of COVID-19 earlier in an infection.
    • On-site assessment (as little as 11-mins for positive status up to 30-min for result confirmation) will minimize result turnaround time and improve resident health management pathways at Loch Lomond Villa.

    EMERYVILLE, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health" or "Lucira"), a medical technology company, and Loch Lomond Villa, one of New Brunswick's largest long-term health facility operators announced today a clinical study to simultaneously test residents, medical and support staff, and visitors for COVID-19 and Influenza A/B infection with the Lucira COVID-19 & Flu Test.

    This pilot will significantly enhance testing and tracking capabilities at Loch Lomond Villa, while allowing medical staff to conduct a comparative and observational study that will help assess the effectiveness of Lucira's testing platform in managing and minimizing COVID-19 and Influenza A/B outbreaks in long-term care settings. Lucira's COVID-19 & Flu Test, the first and only 99% accurate molecular self-test, can provide immediate testing and accurate PCR (polymerase chain reaction) test results for all three viruses.

    "Effective testing is the first line of defense in managing respiratory outbreaks," said Loch Lomond Villa Chief Executive Officer, Ms. Cindy Donovan. "The ability of Lucira's platform to simultaneously test for influenza A/B and COVID-19 has the potential to make a huge difference to our residents and staff. We look forward to analyzing and reporting the results."

    "Lucira's test means that Canadians no longer need to trade-off speed for accuracy when testing for infection," said Erik Engelson, President and Chief Executive Officer of Lucira Health. "This is the only portable molecular self-test for COVID-19 and the flu on the market, providing lab-quality test results, at home and work, in hospitals or while travelling."

    The Lucira COVID-19 & Flu Test is also available for direct purchase by Canadians on Lucira's website: lucirahealth.ca.

    About Lucira COVID-19 & Flu Test

    The Lucira COVID-19 & Flu Test is a NAAT test utilizing the same platform and device design as Lucira's COVID-19 Test to provide independent diagnoses for COVID-19, Flu A, and Flu B. The single-use test fits in the palm of your hand, runs on two AA batteries, and with one nasal swab, provides a positive or negative result for COVID-19, Flu A, and Flu B in 30 minutes or less. Each Lucira test is packaged with everything needed to run a single test: the test device, two AA batteries, sample vial, swab, and simple instructions. There is no separate reader or instrument to purchase and maintain.

    About Lucira Health

    Lucira is a medical technology company focused on the development and commercialization of innovative infectious disease tests to make lab-quality diagnostics more accessible. Lucira designed its test platform to provide accurate, reliable, PCR-quality test results anywhere and at any time. Beyond its already commercialized COVID-19 and COVID-19 & Flu Tests, Lucira is working on new diagnostic tests for respiratory infections and other categories including women's health and sexually transmitted infections (STIs). For more information, visit www.lucirahealth.com.

    About Loch Lomond Villa

    Loch Lomond Villa officially opened its doors in 1973, thanks to the vision and support of East Saint Johns Simonds Lions Club, who foresaw the need for a complete life-care centre for the Saint John area senior population. Loch Lomond Villa's person-centered approach means providing individualized care for all residents and applying the highest standards of care to everything we do. We are focused on the elements of care and support that matter most to residents and their families. In October of 2019, Loch Lomond Villa was awarded Gold Certification for Excellence in Person-Centered Care by Planetree International. This Person-Centered Care Certification recognizes Loch Lomond Villa's achievement and innovation in the delivery of person-centered care. Loch Lomond Villa is one of only 90 healthcare organizations worldwide to receive the Person-Centered Care Gold Certification since the program's launch in 2007. Loch Lomond Villa is also accredited through Accreditation Canada with exemplary status.

    Media:

    English Canada Media: Holly Windler [email protected]– +1 619-929-1275

    Québec & Francophone Media: Martin Croteau [email protected] – 418-956-6898

    Investor Relations:

    Greg Chodaczek [email protected] – 347-620-7010

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5881b5b9-52d8-4c9a-a0f2-32b880928555



    Primary Logo

    Get the next $LHDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LHDX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LHDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lucira Health downgraded by William Blair

    William Blair downgraded Lucira Health from Market Outperform to Market Perform

    5/4/21 6:46:28 AM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lucira Health downgraded by BofA Securities with a new price target

    BofA Securities downgraded Lucira Health from Neutral to Underperform and set a new price target of $9.00

    4/13/21 6:49:01 AM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    William Blair initiated coverage on Lucira Health

    William Blair initiated coverage of Lucira Health with a rating of Outperform

    3/8/21 8:22:19 AM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LHDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Engelson Erik T. exercised 574,666 shares at a strike of $0.82 and sold $657,306 worth of shares (634,666 units at $1.04), decreasing direct ownership by 72% to 23,282 units

    4 - Lucira Health, Inc. (0001652724) (Issuer)

    3/13/23 6:30:09 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4: Narido Richard Clavano sold $29,423 worth of shares (29,383 units at $1.00), decreasing direct ownership by 27% to 77,910 units

    4 - Lucira Health, Inc. (0001652724) (Issuer)

    3/13/23 5:10:58 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4: Collins Kevin Walter sold $73,841 worth of shares (111,819 units at $0.66), decreasing direct ownership by 32% to 234,903 units

    4 - Lucira Health, Inc. (0001652724) (Issuer)

    3/13/23 5:09:40 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LHDX
    SEC Filings

    View All

    SEC Form 15-12G filed by Lucira Health Inc.

    15-12G - Lucira Health, Inc. (0001652724) (Filer)

    10/4/23 3:31:57 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lucira Health Inc. filed SEC Form 8-K: Other Events, Bankruptcy or Receivership

    8-K - Lucira Health, Inc. (0001652724) (Filer)

    9/25/23 4:01:01 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form NT 10-Q filed by Lucira Health Inc.

    NT 10-Q - Lucira Health, Inc. (0001652724) (Filer)

    8/15/23 4:00:25 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LHDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Lucira Health Inc. (Amendment)

    SC 13D/A - Lucira Health, Inc. (0001652724) (Subject)

    12/22/22 3:17:39 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LHDX
    Financials

    Live finance-specific insights

    View All

    Lucira Health Announces Third Quarter 2022 Results and Provides Business Updates

    EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the third quarter ended September 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $34.4 million for the third quarter of 2022, an increase of 130% over the third quarter of 2021.Executed a marketing agreement with Pfizer to increase awareness of the risks of COVID-19 and the availability of treatment. Partnered with telehealth marketplace, Sesame Care

    11/14/22 4:02:00 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lucira Health to Announce Third Quarter 2022 Financial Results

    EMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14th, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsInvestors interested in listening to the conference call should reg

    11/1/22 7:00:00 AM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lucira Health Announces Second Quarter 2022 Results and Provides Business Updates

    EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the second quarter ended June 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $26.1 million for the second quarter of 2022, an increase of 110% over the second quarter of 2021Received regulatory approval in Canada for the COVID-19 & Flu test with Self Test at Home indication and a full exemption by the New Zealand Ministry of Health for COVID-19 testSc

    8/15/22 4:01:00 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LHDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lucira Health Announces FDA Authorization of First & Only At-Home Combination Covid-19 & Flu Test and Comments on Chapter 11 Bankruptcy Filing

    Lab-quality results for both COVID-19 and Flu now available at home from one single testCOVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access time-sensitive prescription treatment optionsLucira's COVID-19 & Flu Home Test demonstrated similar performance for COVID-19, Flu A and Flu B in head-to-head comparison study with highly sensitive lab-based PCR testsLucira seeks a strategic or financial partner for resumption of manufacturing and development of additional home diagnostic products EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health" or "Lucira"), a medical technology company,

    2/27/23 8:00:00 AM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lucira Health to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

    EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company, announced today that it has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its customers during the Chapter 11 process. Lucira Health grew rapidly over the past several years as the COVID-19 pandemic spread throughout the world. Demand for the Company's COVID-19 test kits surged and the Company p

    2/22/23 5:15:48 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SESAME PARTNERS WITH LUCIRA HEALTH AS OFFICIAL TELEHEALTH PROVIDER OF LAB-QUALITY TEST-TO-TREAT PROGRAM

    New partnership enables a free Sesame telehealth consultation with purchase of a Lucira at-home COVID-19 test, providing a full test-to-treat experience from the comfort of home, within two hours NEW YORK , Jan. 5, 2023 /PRNewswire/ -- Sesame, the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans, and Lucira Health, Inc. ("Lucira Health" or "Lucira") today announced their national partnership to increase access to high-quality, convenient and affordable COVID-19 testing and treatment. Via Lucira Connect, a recently-launched virtual care platform, patients who purchase Lucira's COVID-19 Test can now easily learn about treatment opt

    1/5/23 9:00:00 AM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care